We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Other degenerative diseases of the nervous systemOrganic, including symptomatic, mental disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Before a patient is diagnosed with Alzheimer’s Disease (AD) dementia, they may be diagnosed with Mild Cognitive Impairment (MCI). This is when they start to experience problems with memory, language, thinking and judgment, worse than would be expected with normal ageing. But the problem is that MCI does not always lead to dementia, and not knowing can cause uncertainty and worry.
A new technique called Cortical Disarray Measurement (CDM), which uses normal MRI brain scans, may be able to reveal microscopic changes taking place in the brain’s “grey matter”. These changes are normally only seen in the brain through a microscope after a patient has passed away and may be able to be used to identify people with MCI who are likely to progress to Alzheimer’s disease.
The project aims to demonstrate the use of CDM for identification of individuals who progress to dementia. The project also aims to understand how the technology can best help doctors and patients, and to complete a health economics analysis to see whether it could provide savings for patient care in diagnosis and prognosis.
We will complete a longitudinal cohort study, where 200 participants with MCI and mild AD and their companions will be recruited. Participants will be recruited through secondary and tertiary centres where diagnostic investigation or patient monitoring is underway. Participants will be followed for two years at 6 monthly intervals to determine change on standard cognitive and functional measures with MRI examination at baseline and 24 months. The study is observational and will not change normal clinical care.
Optional substudies will be completed for 1) collection of biosamples for Alzheimer’s disease biomarkers and future research and 2) qualitative analysis of patient views and experiences regarding their diagnostic pathway and the potential value of CDM.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patient participants must not meet the following criteria: • Do not meet the inclusion criteria. • No study companion available. • Individuals with a non-progressive learning disability. • Are not fluent in English. • Are pregnant. Companion participants: • A condition or reason, in the investigator’s judgement, that would question the validity of the acquired companion reported data. • Individuals who are not fluent in English.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 51886
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
